Alucent Biomedical
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Development of a drug-device combination for treating vascular diseases.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Company founded
Alucent Biomedical is founded by the Avera Research Institute, part of the Avera Health System, to commercialize its Natural Vascular Scaffolding (AlucentNVS) technology for treating vascular disease without permanent implants such as stents.
- Series B financing
The company closes a $35 million Series B round led by a large multinational strategic investor and joined by Fresenius Medical Care Ventures, bringing total funding to about $60 million, to support the ACTIVATE I and ACTIVATE II clinical trials for peripheral artery disease.
- FDA clinical approvals
The FDA grants two Investigational Device Exemptions for U.S. clinical studies of AlucentNVS technology, including a study for promoting the maturation of arteriovenous fistulas in hemodialysis patients, with the Activate AVF feasibility trial enrolling patients in Australia and Poland.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.